Overview

Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer

Status:
Withdrawn
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The current study will test single agent IL-2 in stage IV melanoma and kidney cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Loma Linda University
Treatments:
Interleukin-2